Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS)
Can meditation influence quality of life, depression, and disease outcome in multiple sclerosis? Findings from a large international web-based study.
Drawing on related knowledge to advance multiple sclerosis falls-prevention research.
Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-α-dependent mechanism.
PGE2/EP4 signaling in peripheral immune cells promotes development of experimental autoimmune encephalomyelitis.
FTY720 inhibits tubulointerstitial inflammation in albumin overload-induced nephropathy of rats via the Sphk1 pathway.
Does the six-minute walk test measure walking performance or physical fitness in persons with multiple sclerosis?
NLRP3 inflammasome and its inhibitors: a review.
Tryptophan Metabolites and Their Impact on Multiple Sclerosis Progression.
Altered functional connectivity and performance variability in relapsing-remitting multiple sclerosis.
Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity.
One year follow-up of a pragmatic multi-centre randomised controlled trial of a group-based fatigue management programme (FACETS) for people with multiple sclerosis.
No association between identified multiple sclerosis non-MHC risk loci and neuromyelitis optica.
Seminal vesicle fluid ameliorates experimental autoimmune encephalomyelitis by increasing FoxP3(+) regulatory T-cell numbers.
Evaluation of the Innermost Retinal Layers and Visual Evoked Potentials in Patients with Multiple Sclerosis.
The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris.
Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Assessing dalfampridine efficacy in the physician's office.
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
Hrd1-mediated BLIMP-1 ubiquitination promotes dendritic cell MHCII expression for CD4 T cell priming during inflammation.
Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.
Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - NO.
Financial Incentives, Workplace Wellness Program Participation, and Utilization of Health Care Services and Spending.
MOG-induced experimental autoimmune encephalomyelitis in the rat species triggers anti-neurofascin antibody response that is genetically regulated.
Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis.

Pages